OncoMed Pharmaceuticals
- Company typePrivate
- Founded2004
- HeadquartersRedwood City, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
OncoMed Pharmaceuticals firmographics
Firmographics- Name
- OncoMed Pharmaceuticals
- Website
- https://oncomed.com
- Company type
- Private
- Founded year
- 2004
- Headcount range
- 51–100 employees
- Ownership category
- akta.pro rank
OncoMed Pharmaceuticals industry classification
Industry- Product category
- Oncology Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Oncology Specialty Pharmaceuticals (HLAIACAA)
- akta.pro secondary industry
- Oncology & Hematology Pharmaceuticals (HLAIAAAC)
Keywords
Where OncoMed Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Redwood City
- HQ country
- United States
- HQ region
- North America
Markets served
OncoMed Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Revenue model
- Therapeutic Development and Licensing: Mereo BioPharma develops novel therapeutic candidates for rare diseases. The company funds and develops high-potential novel therapies that were not being progressed in pharmaceutical or biotechnology companies for strategic reasons. Programs have received significant capital investment from originator companies, including in clinical development. The company also out-licenses clinical stage programs.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels5 records
OncoMed Pharmaceuticals product offering
Product offeringCore offering
OncoMed Pharmaceuticals is a biotechnology company that develops novel therapeutics for the treatment of cancer. The firm operates as a clinical-stage biopharmaceutical company focused on discovering and advancing oncology drug candidates.
Differentiator
Problem solved
Functional benefit
Quantifiable outcome
- Black Pearl Company Award for Patient Engagement (2025) - recognizing commitment to serving and empowering people living with rare conditions through meaningful collaboration
Companies that use OncoMed Pharmaceuticals
Customer profileSegments3 records
Ideal customer profiles1 record
OncoMed Pharmaceuticals technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
OncoMed Pharmaceuticals partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- UltragenyxcoreMereo and partner Ultragenyx received the Black Pearl Company Award for Patient Engagement in February 2025. This award recognizes their commitment to serving and empowering people living with rare conditions through meaningful collaboration. The partnership involves advancing rare disease therapies, specifically the Setrusumab UX-143 program for osteogenesis imperfecta.
Scale indicators3 records
Recent moves6 records
Expansion highlights2 records
OncoMed Pharmaceuticals competitors and assessment
Company assessmentBroad incumbents
- Exelixis: Exelixis is a commercial-stage oncology biotech headquartered in the San Francisco Bay Area that developed targeted oncology therapeutics, providing a regional and category benchmark for the trajectory available to clinical-stage Bay Area oncology biotechs.
- Seagen (formerly Seattle Genetics): Seagen is an established oncology biopharmaceutical company developing targeted cancer therapies, serving as a benchmark for the clinical-to-commercial trajectory that successful Bay Area oncology biotechs can follow.
- Acceleron Pharma: Acceleron Pharma was a clinical-to-commercial biopharmaceutical company developing therapeutics for rare diseases and oncology, offering a comparable model in clinical-stage biotech profile and eventual strategic exit trajectory (acquired by Merck).
Direct peers
- Array BioPharma: Array BioPharma was a clinical-stage oncology-focused biopharmaceutical company with multiple targeted oncology programs, ultimately acquired by Pfizer — comparable in pipeline breadth, oncology focus, and clinical-stage biotech profile.
- Mereo BioPharma: Mereo BioPharma is the acquirer of OncoMed Pharmaceuticals and operates as a clinical-stage biopharmaceutical company. Direct comparability stems from shared clinical-stage biotech business model and from the merger itself, which makes Mereo the most material direct counterparty in OncoMed's trajectory.
- Five Prime Therapeutics: Five Prime Therapeutics was a clinical-stage biotech focused on oncology and immuno-oncology with a multi-program pipeline, comparable in scale, multi-asset strategy, and ultimate strategic outcome (acquired by Amgen).
- MacroGenics: MacroGenics is a clinical-stage biopharmaceutical company developing antibody-based therapeutics for cancer with a multi-program pipeline, paralleling OncoMed's portfolio strategy and clinical-stage oncology profile.
- Stemline Therapeutics: Stemline Therapeutics was a clinical-stage oncology biopharmaceutical company developing therapeutics for difficult-to-treat cancers, comparable to OncoMed in scale, oncology focus, and clinical-stage biotech profile (acquired by Menarini).
Market position
Strengths3 records
Weaknesses4 records
Competitive moat3 records
Key risks4 records
Key highlights5 records
Customer concentration
OncoMed Pharmaceuticals social profiles
Digital presenceOncoMed Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
OncoMed Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles1 record
OncoMed Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds4 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
OncoMed Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about OncoMed Pharmaceuticals
What does OncoMed Pharmaceuticals do?
OncoMed Pharmaceuticals is a biotechnology company that develops novel therapeutics for the treatment of cancer. The firm operates as a clinical-stage biopharmaceutical company focused on discovering and advancing oncology drug candidates.
When was OncoMed Pharmaceuticals founded?
OncoMed Pharmaceuticals was founded in 2004. It employs 51 to 100 people.
Where is OncoMed Pharmaceuticals based?
OncoMed Pharmaceuticals is headquartered in Redwood City, United States, in the North America region.
How does OncoMed Pharmaceuticals make money?
One revenue line is on record: therapeutic Development and Licensing.
Who are OncoMed Pharmaceuticals's main competitors?
Broad incumbents on record are Exelixis, Seagen (formerly Seattle Genetics) and Acceleron Pharma. Direct peers are Array BioPharma, Mereo BioPharma, Five Prime Therapeutics, MacroGenics and Stemline Therapeutics.
Does OncoMed Pharmaceuticals have an API?
No public API is recorded for OncoMed Pharmaceuticals.
What industry is OncoMed Pharmaceuticals in?
OncoMed Pharmaceuticals's product category is Oncology Therapeutics. Its primary akta.pro industry code is HLAIACAA, Oncology Specialty Pharmaceuticals, with a secondary code of HLAIAAAC, Oncology & Hematology Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2834.